Educational & Guideline Reference Notice: Unranked FDA-label and national guideline option categories and recruiting clinical trials for discussion with a licensed oncologist. Protocol drug dosing and autonomous treatment prescriptions are excluded.
Colorectal Cancer (CRC) — Options & Clinical Trial Reference
Source-cited reference covering MMR/MSI status, KRAS/NRAS, BRAF V600E, HER2 amplification, sidedness, surgical/systemic settings, and recruiting trials.
Key Biomarkers & Decision Factors:
biomarkerspending_status_values
biomarkerspending_status_values
Unranked Guideline & FDA-Label Option Categories (34 total)
| Option / Pathway | Category | Primary Sources |
|---|---|---|
| Stage 0/I colon local treatment review | care_pathway | NCI-COLON |
| Stage II colon observation discussion | care_pathway | NCI-COLON, pdq_colon |
| Stage II colon adjuvant risk/benefit review | conventional_therapy | NCI-COLON, pdq_colon, FDA-DPD, FDA-XELODA-2025, xeloda |
| Stage II dMMR colon specialist review | care_pathway | NCI-COLON, pdq_colon |
| Stage III colon FOLFOX / CAPOX review | conventional_therapy | FDA-DPD, FDA-XELODA-2025, LABEL-OXALIPLATIN, NCI-COLON, pdq_colon, pm_29590544, pm_29611518, oxaliplatin |
| Stage 0/I rectal local treatment review | care_pathway | NCI-RECTAL |
| Locally advanced rectal total neoadjuvant therapy review | conventional_therapy | NCI-RECTAL, pdq_rectal, pm_35483010, pm_37883738, pm_33301740, pm_33862000, FDA-DPD, FDA-XELODA-2025 |
| Lower-risk locally advanced rectal selective-radiation discussion | care_pathway | NCI-RECTAL, pdq_rectal, pm_37272534, FDA-DPD, LABEL-OXALIPLATIN |
| Dostarlimab (JEMPERLI) for MSI-H or dMMR stage II/III locally advanced rectal cancer | biomarker_selected_therapy | LABEL-JEMPERLI-2026-10, pdq_rectal |
| Rectal complete-response organ-preservation discussion | care_pathway | NCI-RECTAL, pdq_rectal, pm_35483010, pm_37883738 |
| Potentially curable metastatic local-treatment review | care_pathway | NCI-COLON, pdq_colon, pdq_rectal |
| Pembrolizumab first-line review | biomarker_selected_therapy | FDA-PD1 |
| Nivolumab + ipilimumab review | biomarker_selected_therapy | FDA-NIVO-IPI, opdivo |
| FOLFOX / FOLFIRI + anti-VEGF review | conventional_therapy | NCI-COLON, pdq_colon, avastin, FDA-DPD, FDA-XELODA-2025, LABEL-BEVACIZUMAB, LABEL-IRINOTECAN, LABEL-OXALIPLATIN |
| Left-sided RAS/BRAF-wild-type doublet + anti-EGFR review | biomarker_selected_therapy | NCI-COLON, pdq_colon, erbitux, vectibix, pm_35666229, FDA-DPD, FDA-XELODA-2025, LABEL-IRINOTECAN |
Recruiting Clinical Trials (507 curated)
| NCT ID | Study Title | Phase |
|---|---|---|
| NCT01174121 | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer | PHASE2 |
| NCT01365169 | Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients" | NA |
| NCT02000089 | The Cancer of the Pancreas Screening-5 CAPS5)Study | PHASE3 |
| NCT02172651 | Vitamin D in Patients With Stage I-III Colon Cancer or Resectable Colon Cancer Liver Metastases | EARLY_PHASE1 |
| NCT02448173 | A Multicenter Study of Active Specific Immunotherapy With OncoVax® in Patients With Stage II Colon Cancer | PHASE3 |
| NCT02584244 | Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers | PHASE1|PHASE2 |
| NCT02600949 | Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer | PHASE1 |
| NCT03051464 | Randomizing Two Radiotherapy Boost Options to Avoid Rectal Cancer Surgery | PHASE2|PHASE3 |
| NCT03093116 | A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements | PHASE1|PHASE2 |
| NCT03175224 | APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors | PHASE2 |
| NCT03190941 | Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients | PHASE1|PHASE2 |
| NCT03516708 | Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer | PHASE1|PHASE2 |